Encompass Health Corp EHC.N, EHC is expected to show a rise in quarterly revenue when it reports results on August 5 for the period ending June 30 2024
The Birmingham Alabama-based company is expected to report a 9.9% increase in revenue to $1.305 billion from $1.19 billion a year ago, according to the mean estimate from 11 analysts, based on LSEG data.
LSEG's mean analyst estimate for Encompass Health Corp is for earnings of $1.01 per share.
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 12 "strong buy" or "buy," "hold" and "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Encompass Health Corp is $97.00, above its last closing price of $93.02.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING |
STARMINESMARTESTIMATE® |
LSEG IBES ESTIMATE |
ACTUAL |
BEAT, MET, MISSED |
SURPRISE % |
Mar. 31 2024 |
0.94 |
0.94 |
1.12 |
Beat |
19.7 |
Dec. 31 2024 |
0.82 |
0.82 |
0.95 |
Beat |
16.4 |
Sep. 30 2023 |
0.78 |
0.77 |
0.86 |
Beat |
11.8 |
Jun. 30 2023 |
0.75 |
0.75 |
0.95 |
Beat |
27.5 |
Mar. 31 2023 |
0.70 |
0.70 |
0.88 |
Beat |
25.1 |
Dec. 31 2022 |
0.83 |
0.83 |
0.88 |
Beat |
5.8 |
Sep. 30 2022 |
0.65 |
0.64 |
0.67 |
Beat |
5 |
Jun. 30 2022 |
0.92 |
0.97 |
0.89 |
Missed |
-8 |
This summary was machine generated August 2 at 20:28 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)